[The importance of bone management for cancer bone disease--positioning of zoledronic acid for multiple myeloma, genitor-urinary cancers (renal cancer and prostate cancer), lung cancer and breast cancer].
With the advances in early diagnosis and treatment of cancer, prognosis of cancer patients has been improved significantly. Therefore improvement of QOL for cancer patients has become an important issue. Prevention of skeletal related event is one of the major factors to improve QOL in patients with bone metastasis. Since the clinical introduction of zoledronic acid, management of bone lesions has been improved and decreased SRE significantly. The specialists from four disease area which is multiple myeloma, urological cancer, lung cancer and breast cancer have discussed the benefits (and risks?) of the zoledronic acid with the current status of bone management in each cancer.